Annals of Hematology

, Volume 98, Issue 8, pp 1953–1959 | Cite as

Incidence of lymphoma in HIV-HCV-infected patients. Modifications in function of the anti-hepatitis C virus therapy

  • Daniel Gutiérrez-Saborido
  • Alicia Gutiérrez-Valencia
  • Carmen María González Domenech
  • Miguel Ángel López Ruz
  • Miguel Raffo Márquez
  • Mohamed Omar
  • José Antonio Girón-GonzálezEmail author
  • Grupo de Estudio de Hepatitis Virales (HEPAVIR) of the Sociedad Andaluza de Enfermedades Infecciosas (SAEI)
Original Article


The change in the incidence of lymphomas in function of the presence or absence of sustained virological response after anti-hepatitis C therapy in a cohort of human immunodeficiency (HIV)-hepatitis C (HCV) viruses coinfected patients was analyzed. A prospective cohort of 755 HIV-HCV coinfected patients who received their first anti-HCV therapy, based on interferon + ribavirin schemas, was evaluated. Incidence and histologic types of lymphomas were analyzed in two periods: (1) before administration of anti-HCV therapy and (2) after anti-HCV therapy. The association between lymphoma incidence and demographic, HIV- (minimum CD4+ cell count and CD4+ cell count at diagnosis of lymphoma, antiretroviral therapy, maximal HIV load and HIV load at diagnosis of lymphoma) and HCV-related variables (HCV load, genotype, sustained viral response to anti-HCV therapy) were analyzed. A total of 13 lymphomas [incidence rate (95% confidence interval), 0.72 (0.33–1.11) × 1000 person-years, time from HIV diagnosis to lymphoma diagnosis (median, interquartile range), 15 (11–19) years] were diagnosed. Nine of them were non-Hodgkin and four Hodgkin lymphomas. The median CD4+ T cell count at diagnosis of lymphoma was 457/mm3, with only two cases with values lower than 200/mm3. The incidence rate of non-Hodgkin lymphomas was similar pre- and post-anti HCV therapy [0.33 (0.00–0.65) vs 0.68 (0.08–1.26) × 1000 person-years, respectively, p > 0.05]. Patients with sustained virologic HCV response showed similar incidence rate of lymphomas than that of those without anti-HCV response. In conclusion, anti-HCV therapy does not modify the incidence rate of lymphomas in HIV-HCV coinfected patients.


HIV Hepatitis C virus Non-Hodgkin lymphoma Hodgkin lymphoma Interferon alpha Ribavirin 



The corresponding author had full access to all study data and final responsibility for the decision to submit for publication.

Authors’ contributions

Study conception and design: Gutiérrez-Saborido D, Girón-González JA.

Acquisition of data: Daniel Gutiérrez-Saborido, Alicia Gutiérrez-Valencia, Carmen María González Domenech, Miguel Angel López Ruz, Miguel Raffo Marquez, Mohamed Omar, José Antonio Girón-González.

Drafting of manuscript: Gutiérrez-Saborido D, Girón-González JA.

Critical revision: Daniel Gutiérrez-Saborido, Alicia Gutiérrez-Valencia, Carmen María González Domenech, Miguel Angel López Ruz, Miguel Raffo Marquez, Mohamed Omar, José Antonio Girón-González.

Compliance with ethical standards

The ethics committee of the Hospital Universitario Puerta del Mar, Cadiz (Spain) approved the study. Informed consent was obtained from all patients for being included in the study.

Conflict of interest

The authors declare that they have no competing interests.


  1. 1.
    Carbone A, Gloghini A (2005) AIDS-related lymphomas: from pathogenesis to pathology. Br J Haematol 130:662–670CrossRefGoogle Scholar
  2. 2.
    Shiels MS, Pfeiffer RM, Hall HI, Li J, Goedert JJ, Morton LM, Hartge P, Engels EA (2011) Proportions of Kaposi sarcoma, selected non-Hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS, 1980-2007. JAMA 305:1450–1459CrossRefGoogle Scholar
  3. 3.
    Gopal S, Patel MR, Yanik EL, Cole SR, Achenbach CJ, Napravnik S, Burkholder GA, Reid EG, Rodriguez B, Deeks SG, Mayer KH, Moore RD, Kitahata MM, Eron JJ, Richards KL (2013) Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst 105:1221–1229CrossRefGoogle Scholar
  4. 4.
    Gisbert JP, García-Buey L, Pajares JM, Moreno-Otero R (2003) Prevalence of hepatitis C virus infection in B-cell non-Hodgkin’s lymphoma: systematic review and meta-analysis. Gastroenterology 125:1723–1732CrossRefGoogle Scholar
  5. 5.
    Matsuo K, Kusano A, Sugumar A, Nakamura S, Tajima K, Mueller NE (2004) Effect of hepatitis C virus infection on the risk of non-Hodgkin’s lymphoma: a meta-analysis of epidemiological studies. Cancer Sci 95:745–752CrossRefGoogle Scholar
  6. 6.
    Nieters A, Kallinowski B, Brennan P, Ott M, Maynadié M, Benavente Y, Foretova L, Cocco PL, Staines A, Vornanen M, Whitby D, Boffetta P, Becker N, de Sanjosé S (2006) Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH. Gastroenterology 131:1879–1886CrossRefGoogle Scholar
  7. 7.
    Arcaini L, Vallisa D, Rattotti S, Ferretti VV, Ferreri AJM, Bernuzzi P, Merli M, Varettoni M, Chiappella A, Ambrosetti A, Tucci A, Rusconi C, Visco C, Spina M, Cabras G, Luminari S, Tucci M, Musto P, Ladetto M, Merli F, Stelitano C, d'Arco A, Rigacci L, Levis A, Rossi D, Spedini P, Mancuso S, Marino D, Bruno R, Baldini L, Pulsoni A (2014) Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. Ann Oncol 25:1404–1410CrossRefGoogle Scholar
  8. 8.
    Kawamura Y, Ikeda K, Arase Y, Yatsuji H, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki F, Suzuki Y, Kumada H (2007) Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med 120:1034–1041CrossRefGoogle Scholar
  9. 9.
    Levine AM, Nelson R, Zuckerman E, Zuckerman T, Govindarajan S, Valinluck B, Bernstein L (1999) Lack of association between hepatitis C infection and development of AIDS-related lymphoma. J Acquir Immune Defic Syndr Hum Retrovirol 20:255–258CrossRefGoogle Scholar
  10. 10.
    Waters L, Stebbing J, Mandalia S, Young AM, Nelson M, Gazzard B, Bower M (2005) Hepatitis C infection is not associated with systemic HIV-associated non-Hodgkin’s lymphoma: a cohort study. Int J Cancer 116:161–163CrossRefGoogle Scholar
  11. 11.
    Engels EA, Frisch M, Lubin JH, Gail MH, Biggar RJ, Goedert JJ (2002) Prevalence of hepatitis C virus infection and risk for hepatocellular carcinoma and non-Hodgkin lymphoma in AIDS. J Acquir Immune Defic Syndr 31:536–541CrossRefGoogle Scholar
  12. 12.
    Wang Q, De Luca A, Smith C et al (2017) Chronic hepatitis B and C virus infection and risk for non-Hodgkin lymphoma in HIV-infected patients: a cohort study. Ann Intern Med 166:9–17CrossRefGoogle Scholar
  13. 13.
    Márquez M, Romero-Cores P, Montes-Oca M, Martín-Aspas A, Soto-Cárdenas MJ, Guerrero F, Fernández-Gutiérrez C, Girón-González JA (2015) Immune activation response in chronic HIV-infected patients: influence of hepatitis C virus coinfection. PLoS One 10:e0119568CrossRefGoogle Scholar
  14. 14.
    Macías J, Girón-González JA, González-Serrano M, Merino D, Cano P, Mira JA, Arizcorreta-Yarza A, Ruíz-Morales J, Lomas-Cabeza JM, García-García JA, Corzo JE, Pineda JA (2006) Prediction of liver fibrosis in HIV/HCV-coinfected patients by simple noninvasive indexes. Gut 55:409–414CrossRefGoogle Scholar
  15. 15.
    Swerdlow SH, Campo E, Harris NL et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. In: Bosman FT, Jaffe ES, Lakhani SR, Ohgaki H (eds) World Health Organization classification of tumours. IARC, Lyon, FranceGoogle Scholar
  16. 16.
    Miralles P, Berenguer J, Ribera JM, Rubio R, Mahillo B, Téllez MJ, Lacruz J, Valencia E, Santos J, Rodríguez-Arrondo F, Pintado V, Grupo de Estudio del SIDA Register of Systemic AIDS-Related Lymphomas (2007) Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors. J Acquir Immune Defic Syndr 44:167–173CrossRefGoogle Scholar
  17. 17.
    Berenguer J, Miralles P, Ribera JM, Rubio R, Valencia E, Mahillo B, Pintado V, Palacios R, Montes ML, Téllez MJ, la Cruz J, Torre-Cisneros J, Rodríguez-Arrondo F, Sepúlveda MA, Gutiérrez F, Peralta G, Boix V (2008) Characteristics and outcome of AIDS-related Hodgkin lymphoma before and after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 47:422–428Google Scholar
  18. 18.
    Ribera JM, Oriol A, Morgades M, González-Barca E, Miralles P, López-Guillermo A, Gardella S, López A, Abella E, García M, on behalf of the PETHEMA, GELTAMO, GELCAB and GESIDA Groups (2008) Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol 140:411–419CrossRefGoogle Scholar
  19. 19.
    Castillo JJ, Bower M, Bruhlmann J et al (2015) Prognostic factors for advanced stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study. Cancer 121:423–431CrossRefGoogle Scholar
  20. 20.
    Ng PP, Kuo C-C, Wang S, Einav S, Arcaini L, Paulli M, Portlock CS, Marcotrigiano J, Tarr A, Ball J, Levy R, Levy S (2014) B-cell receptors expressed by lymphomas of hepatitis C virus (HCV)-infected patients rarely react with the viral proteins. Blood 123:1512–1515CrossRefGoogle Scholar
  21. 21.
    Suarez F, Lecuit M (2015) Infection-associated non-Hodgkin lymphomas. Clin Microbiol Infect 21:991–997CrossRefGoogle Scholar
  22. 22.
    Shimozuma Y, Ito T, Inokuchi M, Uchikoshi M, Miyashita M, Nozawa H, Shimazaki T, Hiroishi K, Imawari M (2010) Reactivation of Epstein-Barr virus in B cells of patients with chronic hepatitis C. J Med Virol 82:2064–2072CrossRefGoogle Scholar
  23. 23.
    Lucidarme D, Foutrein P, Creusy C et al (1994) Prevalence des marqueurs de l’hepatite C, B et D et aspects histopathologiques dans un groupe de toxicomanes intraveineux. Gastroentrol Clin Biol 18:964–968Google Scholar
  24. 24.
    Benhamou Y, Bochet M, Di Martino V et al (1999) Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc group. Hepatology 30:1054–1058CrossRefGoogle Scholar
  25. 25.
    Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, Koziel MJ (2001) Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 33:562–569CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Daniel Gutiérrez-Saborido
    • 1
  • Alicia Gutiérrez-Valencia
    • 2
  • Carmen María González Domenech
    • 3
  • Miguel Ángel López Ruz
    • 4
  • Miguel Raffo Márquez
    • 5
  • Mohamed Omar
    • 6
  • José Antonio Girón-González
    • 1
    Email author
  • Grupo de Estudio de Hepatitis Virales (HEPAVIR) of the Sociedad Andaluza de Enfermedades Infecciosas (SAEI)
  1. 1.Unidad de Enfermedades Infecciosas. Hospital Universitario Puerta del Mar. Facultad de Medicina, Instituto para la Investigación e Innovación en Ciencias Biomédicas de Cádiz (INiBICA)Universidad de CádizCádizSpain
  2. 2.Enfermedades Infecciosas, Microbiología y Medicina Preventiva. Instituto de Biomedicina de Sevilla/Hospital Universitario Virgen del Rocío/CSICUniversidad de SevillaSevillaSpain
  3. 3.Hospital Universitario Virgen de la Victoria, Málaga. Departamento de Microbiología, Facultad de FarmaciaUniversidad de GranadaGranadaSpain
  4. 4.Unidad Enfermedades Infecciosas, Facultad de Medicina. IBSHospital Universitario Virgen NievesGranadaSpain
  5. 5.Unidad Enfermedades InfecciosasHospital Juan Ramón JiménezHuelvaSpain
  6. 6.Unidad de Enfermedades InfecciosasComplejo Hospitalario de JaénJaénSpain

Personalised recommendations